Ilixadencel granted Regenerative Medicine Advanced Therapy by FDA for metastatic kidney cancer
The US Food and Drug Administration (FDA) has designated ilixadencel [...]
Patient-reported outcomes with atezolizumab plus bevacizumab in metastatic kidney cancer
This study describes patient-reported outcomes from the phase 3 IMmotion151 [...]
Targeted therapy dose reduction resulted in better clinical outcomes
A recent post hoc analysis of the results from the [...]
Ilixadencel improves responses and survival in metastatic kidney cancer
Results from a recent phase 2 clinical trial of ilixadencel [...]
First-line treatment of papillary renal cell carcinoma with sunitinib
Papillary renal cell carcinoma (PRCC) is a rare subtype of [...]
Real-world clinical outcomes with first-line sunitinib for metastatic kidney cancer
A paper published in The Oncologist last month analysed real-world [...]
Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer
A recent literature review and network meta-analysis of phase 2/3 [...]
New first-line immunotherapy plus TKI combinations for metastatic kidney cancer
Approval of axitinib plus pembrolizumab and axitinib plus avelumab in [...]
Real world use of targeted therapies in war veterans with kidney cancer
A retrospective study of the use of targeted therapies for [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
